Drug Trial Radar · NCT07257835
Dupilumab Therapy for EGIDs
Last checked: Nov 20, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Jan 1, 2025
Primary completion
Jan 1, 2027
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- Children's Hospital of Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 2, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-center observational study to investigate the efficacy and tolerability of dupilumab in children with refractory eosinophilic gastrointestinal disorders.
Conditions
- Eosinophilic Gastrointestinal Disorders (EGIDs)
Interventions
Dupilumab - Standard DoseDrug
Dose: For patients with weight ≥ 15kg but \< 30kg, take 200mg each time, every two weeks; for those with weight ≤ 30kg but \< 60kg, take 300mg each time, every two weeks; for those with weight ≥ 60kg, take 300mg each time, once a week.
subcutaneous injectionDevice
Dose: For patients with weight ≥ 15kg but \< 30kg, take 200mg each time, every two weeks; for those with weight ≤ 30kg but \< 60kg, take 300mg each time, every two weeks; for those with weight ≥ 60kg, take 300mg each time, once a week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Endoscopic response rateTime frame: week12, week26, week52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
201102
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.